Health · Medical Research · 37 mins ago
Imdelltra combination cuts death risk in small-cell lung cancer trial
Amgen’s Imdelltra was tested with AstraZeneca’s Imfinzi in a Phase 3 trial involving people with small-cell lung cancer.
The treatment was used as maintenance therapy after initial treatment, rather than as the first treatment.
In extensive-stage disease, cancer has spread beyond the lung where it began.
The combination cut the risk of death by 58% compared with Imfinzi alone, according to the trial results.
A separate account said median overall survival with the combination approached two years, but did not give a more exact figure.
These findings matter because they suggest the combination may help people with this aggressive cancer live longer.
The trial results do not state what the next steps are for regulatory approval or treatment guidance.
Amgen said Imdelltra combined with AstraZeneca’s Imfinzi cut the risk of death by 58% compared with Imfinzi alone in a Phase 3 lung cancer trial.
The combination was used as first-line maintenance treatment for certain patients with small-cell lung cancer.
A separate report said overall survival approached two years with tarlatamab combination maintenance after first-line chemoimmunotherapy.
The reports describe results from a large randomized trial, but the available article text gives few further details.
- Who
- Amgen; the treatment combination includes its drug Imdelltra and AstraZeneca’s Imfinzi.
- What
- A Phase 3 trial found the combination cut the risk of death by 58% versus Imfinzi alone. A separate report said median overall survival approached two years with tarlatamab combination maintenance.
- When
- The reports were published on October 24 and October 25, 2026.
- Where
- The first report was filed from Madrid. The trial location is not stated.
- Why
- The treatment was studied as first-line maintenance therapy for small-cell lung cancer after initial treatment.
This story does not have two clearly opposing sides.
Endpoints News reported that the Imdelltra-Imfinzi combination cut the risk of death by 58% versus Imfinzi alone.
MedPage Today reported that overall survival with tarlatamab combination maintenance approached two years.
- Risk of death reduction
- 58% versus Imfinzi alone
- Trial phase
- Phase 3
- Treatment setting
- First-line maintenance
- Disease
- Small-cell lung cancer
- Reported overall survival
- Approached two years